ArticleFrontiers in oncology2025
Case Report: Mucoepidermoid carcinoma in rare locations: a report of two cases.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Quercetin as a Therapeutic Agent for Oral Cancer: Current Evidence and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- Mucoepidermoid carcinoma of the middle ear: a case report.Frontiers in surgery · 2026Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- Case Report: Mucoepidermoid carcinoma of the lung, a challenging diagnosis of an unusual case.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucoepidermoid carcinoma (MEC) is a common malignancy of the salivary glands, accounting for 10-15% of salivary gland tumors. It mostly occurs in the salivary glands and very rarely in the lungs and mammary glands. The incidence of breast MEC is only 0.2% to 0.3% of all primary breast tumors. Pulmonary MEC accounts for only 0.1-0.2% of all lung tumors. This report presents two cases of MEC occurring in rare locations: the left lower lung and the breast. Both cases presented different clinical features and histopathological characteristics. The immunohistochemical analysis of Ki-67, CK5/6, P63 and other positive results also confirmed the diagnosis. Surgical resection was the primary treatment in both cases, with the patient with lung involvement additionally receiving chemotherapy and radiotherapy. These cases underscore the importance of recognizing MEC in atypical locations, as timely diagnosis and proper treatment approaches are vital for improving patient outcomes. From these cases, the complexity of MEC is highlighted and the necessity of precise histopathological diagnosis, especially in rare sites, is emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.